Ricevi le ultime notizie sulle azioni Kezar Life Sciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di KZR

Ultime notizie per

KEZAR LIFE SCIENCES INC

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences Inc

Press Releases

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

AlphaTON Capital

Boundless Bio

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Elutia

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Evaxion

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

IO Biotech

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Leap Therapeutics

Moleculin Biotech

Mural Oncology

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

Nanoviricides

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

Comments

Kezar Life Sciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO